PerM1: A Non-Coding RNA Molecule as A Potential Drug Target for Muscle Diseases

Target Name: PERM1

NCBI ID: G84808

PERM1

Other Name(s): PGC-1 and ERR-induced regulator in muscle 1 | PPARGC1 and ESRR induced regulator, muscle 1 | C1orf170 | PPARGC1 and ESRR-induced regulator in muscle 1 | RP11-54O7.8 | peroxisome proliferator-activated receptor gamma coactivator 1 and estrogen-related receptor-induced regulator in muscle 1 | pGC-1 and ERR-induced regulator in muscle protein 1

PerM1: A Non-Coding RNA Molecule as A Potential Drug Target for Muscle Diseases

PerM1 (Peroxisome Proliferation-Induced Gene 1) is a non-coding RNA molecule that has been identified as a potential drug target (1) and a biomarker for muscle diseases. It is a key regulator of muscle growth and development, and Its dysfunction has been implicated in a number of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases.

PerM1 is a peroxisome-derived gene that is expressed in various tissues, including muscle, heart, and brain. It is a transcription factor that has been shown to regulate the expression of several target genes involved in muscle development, function, and repair. One of its most well-studied functions is its role in muscle growth and maintenance. PerM1 has been shown to be involved in the regulation of muscle protein synthesis and in the control of muscle cell size.

PerM1 is also involved in the regulation of muscle cell survival and in the development of muscle plasticity. It has been shown to play a role in the regulation of cell apoptosis, a process that is important for muscle cell renewal and regeneration. Additionally , PerM1 has been shown to be involved in the regulation of muscle fiber type composition and in the development of muscle fibers with different properties.

PerM1 has also been implicated in a number of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases. Its dysfunction has been implicated in the development of muscle weakness and fatigue, as well as the loss of muscle mass and muscle function ( 9).

Drugs that target PerM1 have the potential to treat a wide range of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases. For example, studies have shown that inhibitors of PerM1 have the potential to treat muscle dystrophy by preventing muscle cell dysfunction. and muscle wasting. Additionally, PerM1 has been shown to be involved in the regulation of muscle protein synthesis, making it a potential target for muscles disorders associated with protein synthesis deficiencies.

In conclusion, PerM1 is a highly promising drug target and biomarker for a wide range of muscle-related diseases. Further research is needed to fully understand its functions and to develop effective treatments.

Protein Name: PPARGC1 And ESRR Induced Regulator, Muscle 1

Functions: Regulates the expression of selective PPARGC1A/B and ESRRA/B/G target genes with roles in glucose and lipid metabolism, energy transfer, contractile function, muscle mitochondrial biogenesis and oxidative capacity. Required for the efficient induction of MT-CO2, MT-CO3, COX4I1, TFB1M, TFB2M, POLRMT and SIRT3 by PPARGC1A. Positively regulates the PPARGC1A/ESRRG-induced expression of CKMT2, TNNI3 and SLC2A4 and negatively regulates the PPARGC1A/ESRRG-induced expression of PDK4

The "PERM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PERM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets